Johnson & Johnson's Janssen Pharmaceutical Inc. Loses $11 Million Jury Verdict Over Topamax

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Johnson & Johnson (JNJ)’s Janssen Pharmeceuticals unit was ordered by a Philadelphia jury to pay $11 million in a case claiming its anti-seizure drug Topamax caused birth defects, the second such loss in less than a month. Janssen failed to adequately warn doctors for Haley Powell, a stay-at-home mother, of the risks of Topamax before she gave birth to a son with a cleft lip, jurors in state court in Philadelphia found today. “Janssen has long known that this drug causes debilitating birth defects and yet intentionally kept this information from physicians and patients,” Shelley Hutson, an attorney for Powell, said after the verdict was read.

Help employers find you! Check out all the jobs and post your resume.

Back to news